Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer

The effectiveness of targeted therapies against the Ras-ERK signaling pathway are limited due to adaptive resistance of tumor cells. Inhibition of the Ras-ERK pathway can result in activation of the PI3K-AKT pathway, thereby diminishing the therapeutic effects of targeting ERK signaling. Here we inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Cheolwon, Kwon, Junyeob, Lim, Sunyoung, Helfman, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325378/
https://www.ncbi.nlm.nih.gov/pubmed/27563827
http://dx.doi.org/10.18632/oncotarget.11525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325378/
https://www.ncbi.nlm.nih.gov/pubmed/27563827
http://dx.doi.org/10.18632/oncotarget.11525

Ejemplares similares